We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 0.49% | 103.50 | 103.00 | 104.00 | 103.50 | 103.50 | 103.50 | 17,933 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Testing Laboratories | 19.5M | 724k | 0.0086 | 119.77 | 87.01M |
From Apr 2022 to Apr 2024
TIDMDXRX
RNS Number : 1410N
Diaceutics PLC
27 May 2022
27 May 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Issue of and changes to Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of 200,000 share options over ordinary shares of GBP0.002 each in the Company ("Share Options") to certain directors and members of the Company's senior management team as part of their remuneration package and pursuant to the Company's Employee Share Option Plan ("ESOP"), and provides an update on the arrangements for the share options held by Philip White.
Share Options were granted as follows:
Hot Features
Premium
Name Number of Total no. of % of existing Effective
Share Options ordinary shares issued share Grant date
granted under option post capital
grant
Nick Roberts,
CFO 50,000 91,838 0.10% 27 May 2022
-------------- ------------------ ------------- -----------
Julie Browne,
COO and PDMR 50,000 101,938 0.12% 27 May 2022
-------------- ------------------ ------------- -----------
Stefan McDonald,
CGO and PDMR 50,000 131,722 0.16% 27 May 2022
-------------- ------------------ ------------- -----------
Other employees
(1 person) 50,000 96,051 0.11% 27 May 2022
-------------- ------------------ ------------- -----------
The Share Options issued to the Director and CFO, Nick Roberts, vest over three years from the point of employment start (being 18(th) March 2022) and are subject to continued employment.
The Share Options issued to Julie Browne and the other employee vest in tranches over a three-year period from the point of employment start (being 14(th) March 2022 and 1(st) January 2022 respectively), and to Stefan McDonald from the date of his promotion to the Company's senior management team (being 1(st) September 2021) and are subject to continued employment.
The exercise price of the Share Options granted is GBP0.002 per share which equates to the nominal value of the shares.
Following this grant, the total number of share options outstanding in the Company is 3,308,118, representing approximately 3.92% of its current issued share capital of 84,472,431 .
Further to the announcement on 11 January 2022 and, as part of the orderly handover of duties Phillip White (former CFO and Director) is facilitating , the Board has agreed that all his outstanding share options would vest immediately (including those which are currently out of the money). As provided in the scheme rules, these options are require to be exercised within 90 days of vesting.
Phillip White's outstanding share options are as follows:
Number of Grant date Exercise Original Original vesting
Share Options price (pence) vesting period conditions
outstanding
17 April
180,000 2020 126.5 3 years Continued employment
---------- -------------- --------------- ---------------------
Total Shareholder
20 April Return and continued
64,154 2021 0.2 3 years employment
---------- -------------- --------------- ---------------------
The above arrangements with Philip White constitute a related party transaction under the AIM Rules for Companies. The directors, excluding Philip White who is no longer a director, consider, having consulted with the Company's nominated adviser, Stifel Nicolaus Europe Limited, that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned.
Enquiries:
Diaceutics PLC
Peter Keeling, Chief Executive Officer Via Alma PR
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison, Stewart Wallace, Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde, Kieran Breheny, Matthew Young diaceutics@almapr.co.uk
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------
a. Name Nick Roberts
-----------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------
a. Position/Status CFO, Director
------------------------------------- -----------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 50,000
---------------------------------------------------------------------- ---------------
e. Date of the transaction 26 May 2022
------------------------------------- -----------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------
a. Name Julie Browne
-----------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------
a. Position/Status COO and PDMR
------------------------------------- -----------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 50,000
---------------------------------------------------------------------- ---------------
e. Date of the transaction 26 May 2022
------------------------------------- -----------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------
a. Name Stefan McDonald
-----------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------
a. Position/Status CGO and PDMR
------------------------------------- -----------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 50,000
---------------------------------------------------------------------- ---------------
e. Date of the transaction 26 May 2022
------------------------------------- -----------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- ---------------------------------------------------------------------------------------
a. Name Philip White
------------------------------------------------
2 Reason for notification
------------------------------------- ------------------------------------------------
a. Position/Status PDMR
------------------------------------- ------------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- ---------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- ------------------------------------------------
b. Nature of the Change of original vesting conditions of
transaction share options
------------------------------------- ------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 126.5p per
share 180,000
---------------------------------------------------------------------- ----------------
Exercise price
of 0.2p per
share 64,154
---------------------------------------------------------------------- ----------------
e. Date of the transaction 26 May 2022
------------------------------------- ------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- ------------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHARMATMTTTBPT
(END) Dow Jones Newswires
May 27, 2022 11:31 ET (15:31 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
